Chronological coverage of every Litigation Logic post tagged FDA.
-
May 29, 2026Legal News
5th Circuit’s Mifepristone Stay Triggers SCOTUS Emergency Intervention
A unanimous 5th Circuit panel reinstated in-person mifepristone rules nationwide on May 1, overriding the Trump administration’s position before SCOTUS stepped in four days later.
-
May 29, 2026Legal News
Supreme Court Stays Fifth Circuit Order, Preserves Mifepristone Telehealth Access
The Supreme Court stayed a Fifth Circuit order that had reinstated in-person mifepristone dispensing rules, preserving telehealth access while litigation continues below.
-
May 22, 2026Legal News
Fifth Circuit Reinstates Mifepristone In-Person Dispensing Requirement Nationwide
The Fifth Circuit reinstated mifepristone’s in-person dispensing requirement nationwide on May 1, accepting Louisiana’s Medicaid-cost standing theory before the Supreme Court intervened May 4.
-
May 22, 2026Legal News
Supreme Court Stays Fifth Circuit Order Restoring Mifepristone In-Person Requirement
The Supreme Court stayed the Fifth Circuit’s May 1 order reimposing in-person mifepristone rules, preserving telehealth access nationwide while appeals proceed. Thomas and Alito dissented.
-
May 22, 2026Legal News
Supreme Court Freezes 5th Circuit Order Blocking Mail-Order Mifepristone
The Supreme Court indefinitely froze a 5th Circuit ruling that would have ended mail-order mifepristone access, as Alito and Thomas dissented and the Comstock Act emerged as a new front.
-
May 21, 2026Legal News
J&J Toxicologist Deposition Reveals No Evidence Asbestos Report Reached FDA
A J&J toxicologist testified he found no evidence the company shared an asbestos-in-talc report with the FDA, a development that could reshape mass-tort settlement strategy.
-
May 21, 2026Legal News
Supreme Court Stays 5th Circuit Order Reinstating Mifepristone Dispensing Requirement
The Supreme Court blocked a 5th Circuit order that would have reinstated in-person mifepristone dispensing rules, with Thomas invoking the Comstock Act in dissent.
-
May 18, 2026Legal News
5th Circuit Orders Nationwide In-Person Mifepristone Dispensing, Prompting Emergency SCOTUS Action
A 5th Circuit panel reversed a district court stay and ordered nationwide in-person-only mifepristone dispensing, triggering emergency Supreme Court intervention in May 2026.
-
May 17, 2026Legal News
Fifth Circuit Blocks Telehealth and Mail Access to Mifepristone Nationwide
The Fifth Circuit reinstated in-person dispensing rules for mifepristone on May 1, blocking telehealth and mail access nationwide and triggering emergency Supreme Court appeals.
-
May 17, 2026Legal News
Supreme Court Stays 5th Circuit Order Restoring Mifepristone Dispensing Rules
The Supreme Court stayed a 5th Circuit order that would have ended mail-order mifepristone access, with Thomas invoking the Comstock Act in a notable dissent.
-
May 16, 2026Legal News
5th Circuit Bans Mifepristone Mail Distribution; Drugmakers Rush to Supreme Court
The Fifth Circuit voided FDA’s 2021 mail-dispensing rule for mifepristone, banning telehealth prescribing nationwide. The Supreme Court issued an emergency stay May 14.
-
May 16, 2026Legal News
Supreme Court Stays Fifth Circuit Mifepristone Ruling, Preserving Telehealth Access
The Supreme Court stayed the Fifth Circuit’s mifepristone telehealth ban on May 14, preserving mail-order access while two justices raised the Comstock Act as a future threat.
-
May 16, 2026Legal News
Supreme Court Stays Fifth Circuit Order on Mifepristone Dispensing Rules
The Supreme Court stayed a Fifth Circuit order reinstating in-person mifepristone rules, preserving telehealth access while signaling Comstock Act tensions ahead.
-
May 16, 2026Legal Filing
ImmunityBio Securities Fraud Class Action Targets Cancer Drug Claims
A securities fraud class action filed May 11 targets ImmunityBio and CEO Patrick Soon-Shiong over alleged false claims that cancer drug Anktiva was a vaccine.
-
May 15, 2026Legal News
Supreme Court Blocks Fifth Circuit Order Restricting Mail-Order Mifepristone Access
The Supreme Court stayed a Fifth Circuit ruling that would have banned mail-order mifepristone, with seven justices granting relief and Alito dissenting in sharp terms.
-
May 14, 2026Legal News
Fifth Circuit Blocks Mifepristone Mail Access, Drugmakers Rush to Supreme Court
The Fifth Circuit ordered the FDA to reinstate in-person dispensing rules for mifepristone, blocking mail and telehealth access nationally. Drugmakers filed emergency Supreme Court applications.
-
May 14, 2026Legal News
Fifth Circuit Blocks Mifepristone Telehealth Access; Supreme Court Intervenes
A Fifth Circuit panel reinstated mifepristone’s in-person dispensing rule nationwide; Justice Alito issued successive emergency stays as the full Supreme Court deliberated.
-
May 10, 2026Verdict
Federal Jury Convicts Fresno Man on 12 Counts in COVID Test Fraud
A Fresno federal jury convicted Jia Bei Zhu on all 12 counts for selling fake COVID-19 test kits through Universal Meditech Inc., generating $4 million in fraudulent sales.
-
May 6, 2026Legal Filing
5th Circuit Orders FDA to Reinstate Mifepristone In-Person Requirement
The Fifth Circuit ordered the FDA to reinstate in-person mifepristone dispensing on May 1, 2026; the Supreme Court stayed the ruling three days later.
-
May 6, 2026Legal Filing
Alito Issues One-Week Stay Blocking Fifth Circuit Mifepristone Ruling
Justice Alito issued a one-week administrative stay on May 4, 2026, blocking a Fifth Circuit ruling that would have banned mail-order mifepristone access nationwide.
-
May 4, 2026Legal Filing
ImmunityBio Faces Securities Fraud Class Action Over Cancer Drug Claims
A securities fraud class action filed against ImmunityBio targets executive Patrick Soon-Shiong’s claim that cancer drug Anktiva is a vaccine, a description the FDA rejected.